ATE367161T1 - (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)- benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas - Google Patents
(3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)- benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositasInfo
- Publication number
- ATE367161T1 ATE367161T1 AT04815480T AT04815480T ATE367161T1 AT E367161 T1 ATE367161 T1 AT E367161T1 AT 04815480 T AT04815480 T AT 04815480T AT 04815480 T AT04815480 T AT 04815480T AT E367161 T1 ATE367161 T1 AT E367161T1
- Authority
- AT
- Austria
- Prior art keywords
- quinoxaline
- obesity
- dihydro
- oxo
- diabetes
- Prior art date
Links
- VKTAXRVXRXQVOY-UHFFFAOYSA-N 2-[(3-oxo-4h-quinoxalin-2-yl)amino]benzamide Chemical class NC(=O)C1=CC=CC=C1NC1=NC2=CC=CC=C2NC1=O VKTAXRVXRXQVOY-UHFFFAOYSA-N 0.000 title 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 title 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53453404P | 2004-01-06 | 2004-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE367161T1 true ATE367161T1 (de) | 2007-08-15 |
Family
ID=34794290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04815480T ATE367161T1 (de) | 2004-01-06 | 2004-12-22 | (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)- benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20050148586A1 (de) |
| EP (1) | EP1711184B1 (de) |
| JP (1) | JP2007517800A (de) |
| KR (1) | KR20060130159A (de) |
| CN (1) | CN1901917A (de) |
| AR (1) | AR047085A1 (de) |
| AT (1) | ATE367161T1 (de) |
| AU (1) | AU2004313246A1 (de) |
| BR (1) | BRPI0418368A (de) |
| CA (1) | CA2551639A1 (de) |
| CO (1) | CO5700757A2 (de) |
| CR (1) | CR8505A (de) |
| CY (1) | CY1106881T1 (de) |
| DE (1) | DE602004007693T2 (de) |
| DK (1) | DK1711184T3 (de) |
| EA (1) | EA200601287A1 (de) |
| ES (1) | ES2290782T3 (de) |
| HR (1) | HRP20070430T3 (de) |
| IL (1) | IL176648A0 (de) |
| MX (1) | MXPA06007715A (de) |
| NO (1) | NO20063549L (de) |
| PL (1) | PL1711184T3 (de) |
| PT (1) | PT1711184E (de) |
| SI (1) | SI1711184T1 (de) |
| TW (1) | TW200533360A (de) |
| WO (1) | WO2005067932A1 (de) |
| ZA (1) | ZA200606530B (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| AU2009221213B2 (en) | 2008-03-05 | 2014-02-27 | Merck Patent Gmbh | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| ES2548583T3 (es) | 2008-03-05 | 2015-10-19 | Merck Patent Gmbh | Derivados de quinoxalinona como estimuladores de la secreción de insulina, métodos para su obtención y su uso para el tratamiento de la diabetes |
| NZ590503A (en) * | 2008-06-16 | 2012-08-31 | Merck Patent Gmbh | Quinoxalinedione derivatives |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (de) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
| CN109793739A (zh) * | 2019-01-14 | 2019-05-24 | 北京理工大学 | 一种喹喔啉酮衍生物的结构、制备方法及用途 |
| CN112480109B (zh) * | 2020-11-16 | 2022-04-01 | 浙江大学 | 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途 |
| WO2024169848A1 (zh) * | 2023-02-17 | 2024-08-22 | 南京同诺康医药科技有限公司 | miR-124诱导剂及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0008864A1 (de) * | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazin- und Chinoxalinderivate, Verfahren zu ihrer Herstellung, und sie enthaltende pharmazeutische Zusammensetzungen |
| AU674613B2 (en) * | 1993-09-28 | 1997-01-02 | Otsuka Pharmaceutical Co., Ltd. | Quinoxaline derivative as antidiabetic agent |
| SE9800836D0 (sv) * | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
| AU3033500A (en) * | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| AU7738000A (en) * | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
-
2004
- 2004-12-22 WO PCT/US2004/043409 patent/WO2005067932A1/en not_active Ceased
- 2004-12-22 US US11/019,505 patent/US20050148586A1/en not_active Abandoned
- 2004-12-22 PT PT04815480T patent/PT1711184E/pt unknown
- 2004-12-22 JP JP2006547399A patent/JP2007517800A/ja not_active Withdrawn
- 2004-12-22 DK DK04815480T patent/DK1711184T3/da active
- 2004-12-22 AT AT04815480T patent/ATE367161T1/de not_active IP Right Cessation
- 2004-12-22 PL PL04815480T patent/PL1711184T3/pl unknown
- 2004-12-22 CN CNA2004800399887A patent/CN1901917A/zh active Pending
- 2004-12-22 MX MXPA06007715A patent/MXPA06007715A/es not_active Application Discontinuation
- 2004-12-22 SI SI200430449T patent/SI1711184T1/sl unknown
- 2004-12-22 DE DE602004007693T patent/DE602004007693T2/de not_active Expired - Fee Related
- 2004-12-22 EP EP04815480A patent/EP1711184B1/de not_active Expired - Lifetime
- 2004-12-22 ES ES04815480T patent/ES2290782T3/es not_active Expired - Lifetime
- 2004-12-22 AU AU2004313246A patent/AU2004313246A1/en not_active Abandoned
- 2004-12-22 BR BRPI0418368-1A patent/BRPI0418368A/pt not_active Application Discontinuation
- 2004-12-22 CA CA002551639A patent/CA2551639A1/en not_active Abandoned
- 2004-12-22 EA EA200601287A patent/EA200601287A1/ru unknown
- 2004-12-22 HR HR20070430T patent/HRP20070430T3/xx unknown
- 2004-12-22 KR KR1020067015598A patent/KR20060130159A/ko not_active Withdrawn
-
2005
- 2005-01-05 AR ARP050100030A patent/AR047085A1/es not_active Application Discontinuation
- 2005-01-05 TW TW094100198A patent/TW200533360A/zh unknown
-
2006
- 2006-06-29 IL IL176648A patent/IL176648A0/en unknown
- 2006-07-05 CR CR8505A patent/CR8505A/es not_active Application Discontinuation
- 2006-07-14 CO CO06068718A patent/CO5700757A2/es not_active Application Discontinuation
- 2006-08-04 NO NO20063549A patent/NO20063549L/no not_active Application Discontinuation
- 2006-08-04 ZA ZA200606530A patent/ZA200606530B/en unknown
-
2007
- 2007-09-19 CY CY20071101214T patent/CY1106881T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1901917A (zh) | 2007-01-24 |
| HRP20070430T3 (en) | 2007-11-30 |
| PL1711184T3 (pl) | 2007-12-31 |
| KR20060130159A (ko) | 2006-12-18 |
| DE602004007693T2 (de) | 2008-06-05 |
| DK1711184T3 (da) | 2007-11-05 |
| DE602004007693D1 (de) | 2007-08-30 |
| EP1711184A1 (de) | 2006-10-18 |
| CY1106881T1 (el) | 2012-09-26 |
| BRPI0418368A (pt) | 2007-05-15 |
| TW200533360A (en) | 2005-10-16 |
| AR047085A1 (es) | 2006-01-04 |
| IL176648A0 (en) | 2006-10-31 |
| CR8505A (es) | 2008-09-09 |
| NO20063549L (no) | 2006-09-12 |
| MXPA06007715A (es) | 2007-01-26 |
| ES2290782T3 (es) | 2008-02-16 |
| CO5700757A2 (es) | 2006-11-30 |
| ZA200606530B (en) | 2008-02-27 |
| EP1711184B1 (de) | 2007-07-18 |
| SI1711184T1 (sl) | 2007-12-31 |
| PT1711184E (pt) | 2007-09-24 |
| EA200601287A1 (ru) | 2006-10-27 |
| US20050148586A1 (en) | 2005-07-07 |
| CA2551639A1 (en) | 2005-07-28 |
| WO2005067932A1 (en) | 2005-07-28 |
| JP2007517800A (ja) | 2007-07-05 |
| AU2004313246A1 (en) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004007693D1 (de) | (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas | |
| ATE516286T1 (de) | 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes | |
| ATE449604T1 (de) | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren | |
| TW200745037A (en) | Organic compounds | |
| ATE374766T1 (de) | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie | |
| TNSN06315A1 (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes | |
| TN2009000111A1 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| WO2006104826A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| ATE550329T1 (de) | Heterobicyclische sulfonamidderivate zur behandlung von diabetes | |
| WO2007111864A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| WO2008136428A1 (ja) | 含窒素５員複素環化合物 | |
| ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
| WO2007136577A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| NO20073849L (no) | Indolderivater for behandling av virale infeksjoner | |
| MX2007005590A (es) | Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas. | |
| NO20052476D0 (no) | 2-alkyl-(2-amino-3-aryl-propionyl)-piperazinderivater og beslektede forbindelser som melanokortinreseptorligander for behandlingen av obesitet. | |
| DE602008002843D1 (de) | Neue antimikrobielle verbindungen, ihre synthese und ihre verwendung zur behandlung von säugetierinfektionen | |
| ATE486597T1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
| NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
| DE602005021970D1 (de) | Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen | |
| DE602006003538D1 (de) | Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes | |
| DE502006007587D1 (de) | Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung | |
| GEP20125511B (en) | Mapk/erk kinase inhibitors | |
| DE502005002310D1 (de) | Diphenylaminsubstituierte salicylthiazolderivate und verwandte verbindungen als phosphotyrosinphosphatase 1b (ptp1b) hemmer zur verwendung als blutzuckersenkende wirkstoffe zur behandlung von diabetes | |
| ATE466841T1 (de) | 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |